


Product Details

Product name:	Anti-CTLA4 & PD-1 (Vudalimab Biosimilar)	SKU:	BIO1003SM
Target Name:	CTLA4 & PD-1	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	P16410 & Q15116	Concentration:	Lyophilized
Clone#:	Vudalimab (Bispecific)	Isotype:	Half IgG+ScFv
Reactivity:	Human	Calculated M.W.:	125.43 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




The purity of Anti-CTLA4 & PD-1 Reference Antibody (Vudalimab) is 98.25% , determined by SEC-HPLC.

ELISA



Vudalimab bound to CTLA4 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vudalimab bound to hu-CTLA4-His, and the EC₅₀ was 0.480 nM.


ELISA



Vudalimab bound to PD-1 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Vudalimab bound to huPD-1-His, and the EC₅₀ was 0.090 nM.


Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Bioactivity: FACS




Vudalimab bound to CTLA4-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to CTLA4-CHO-K cells, and the EC50 was 20.150 nM.

Bioactivity: FACS



Vudalimab bound to huPD-1-Jurkat cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Vudalimab bound to huPD-1-Jurkat cells, and the EC50 was 2.508 nM.

Function: Luciferase



Co-incubation of Vudalimab with PD-1-NF-AT-Jurkat and CD3L-huPD-L1-CHO-K cells and incubated for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Vudalimab was able to block the PD-1/PD-L1 signaling pathway.